A systematic review and meta-analysis exploring the recruitment hurdles and nonparticipation rate in noninvasive brain stimulation for addictive disorders.

J Addict DisOct 8, 2025 (epub)
Clinical ResearchPsychiatry

Pinki Sevda, Priyanka Saha, Siddharth Sarkar et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and random-effects meta-analysis examined recruitment and nonparticipation in randomized controlled trials of noninvasive brain stimulation for substance-related and behavioral addictive disorders. It included 55 trials identified through searches of major databases. The pooled nonparticipation rate was 55.9% (95% CI: 45.9-65.8%; I 2 = 99.56%, p < 0.001). Commonly reported barriers were not meeting eligibility criteria, anxiety or low motivation, and practical difficulties such as travel or frequent sessions.

Key findings

  • Across 55 randomized trials, the pooled nonparticipation rate was 55.9% (95% CI: 45.9-65.8%; I 2 = 99.56%, p < 0.001).
  • Failure to meet inclusion criteria was reported as a reason for nonparticipation in over 25 studies.
  • At least 15 studies reported refusal related to anxiety or lack of motivation; at least 10 reported logistical barriers such as travel or session frequency.

Why it matters

High nonparticipation can constrain recruitment and may affect how well trial participants represent people with addictive disorders in clinical settings. The reported barriers point to practical and procedural factors that trial teams may need to consider when designing studies. The substantial heterogeneity in the pooled estimate also indicates that nonparticipation varied considerably across trials.

What to keep in mind

The pooled estimate had very high heterogeneity (I 2 = 99.56%), and the review included only peer-reviewed English-language studies that reported screening and randomization counts.

Source

Published in J Addict Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.